DTx

If there are lingering doubts about the viability or market potential of digital therapeutics (DTx), recent moves by the U.S. Food & Drug Administration should lay them to rest. In December 2018, Pear Therapeutics and its partner, Novartis’ Sandoz unit, received FDA clearance for reSET-O, a prescription-only mobile medical app that helps patients with opioid use disorder remain in outpatient treatment programs. The same month, with support from regulators, the ECG app on the Apple Watch 4 became the first direct-to-consumer product that can notify users of an irregular heart rhythm.

 

While these two examples stand out, there are dozens of other software-driven products under regulatory review for diagnosing, treating, or preventing medical conditions. As Sandoz CEO Richard Francis said in a press release announcing the reSET-O, digital therapeutics “have the potential to fundamentally change how patients interact with their therapies,” and may represent “the next chapter of medical innovation.”

 

Read the Full Report Here

Contact Us
Call Our Team 

Phone: +1 919 876 9300
Fax: +1 919 876 9360
Toll-Free: +1 866 462 7373

Authors

Skye Hodson, Engagement Manager, Commercial Advisory Group